Lupin has received final approval for its Metronidazole Tablets USP, 250 mg and 500 mg from the United States Food and Drug Administration (USFDA) to market a generic version of G.D. Searle LLC’s Flagyl Tablets, 250 mg and 500 mg. Flagyl Tablets had US sales of $44.1 million as per IMS MAT June 2017.
The company’s Metronidazole Tablets USP, 250 mg and 500 mg are the AB rated generic equivalent of G.D. Searle LLC’s Flagyl Tablets, 250 mg and 500 mg. It is indicated in the treatment of wide variety of infections which are caused by particular types of bacteria and other infectious organisms.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
